Recruiting

Ariessence

Sponsor:

Lynch Regenerative Medicine

Code:

NCT07718347

Conditions

Immediate Post-Treatment Care

Aging Mid-Face

Aging

Eligibility Criteria

Sex: All

Age: 40 - 70

Healthy Volunteers: Not accepted

Interventions

ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).

Study Details

Brief summary:

ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.

Conditions

Immediate Post-Treatment Care

Aging Mid-Face

Aging

Study ID

NCT07718347

Start date

Apr 16, 2026

Status verified date

Jul, 2026

Completion date

Feb, 2027

Anticipated

Primary completion date

Nov, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria

-:Adults 40-65 70 years

  • Glogau III-IV
  • Fitzpatrick II-IV.
  • Suitable for ablative laser
  • non-smoker ≥ 3 years
  • Willing to comply with post-procedure regimen
  • patient reported outcome documentation, and photo documentation.

Exclusion Criteria:

  • Fitzpatrick I or > IV,
  • recent facial procedures (< 6 months)
  • active skin disease
  • pregnancy/lactation
  • implanted devices
  • history of keloids.

Study Design

Enrollment

21 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: ariessence pure PDGF+

ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).

placebo comparator: standard of care

The non-treatment control group will be treated only with the SOC (Aquaphor or equivalent emoilment) and post-procedure instructions.

Interventions

ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).

To compare time to appearance-based recovery and subject satisfaction between ariessence and standard of care groups using standardized photographs and investigator/subject ratings for tolerability and satisfaction

Primary outcome measure

  • Clinical Measures [ Time Frame: Baseline (Day 0) through Day 84 (End of Study). ]
  • Patient-Reported Outcomes [ Time Frame: Baseline through day 84 ]
  • Photography [ Time Frame: Baseline through Day 84 ]
  • Investigator Objective Tolerability Assessment [ Time Frame: Baseline through Day 84 ]
  • Erythema grading (0-4 scale) [ Time Frame: Baseline through Day 84 (End of Study) ]
  • Clinician's Global Aesthetic Improvement Scale (CGAIS). [ Time Frame: Baseline through Day 84 (End of STudy) ]

Central Contacts and Locations

Central contacts

Josh Arnold

302-604-4532clinicaltrials@purity-health.com

Locations

Laser & Skin Surgery Medical Group

Recruiting

Sacramento, California, United States, 95816

Contacts

Suzanne Kilmer, MD

916-456-0400Nathan.Smith@purity-health.com

The Practice of Brian S. Biesman, MD

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

Brian S Biesman, MD

615-329-1110Nathan.Smith@purity-health.com

More Information

Sponsor

Lynch Regenerative Medicine

Last update posted

Jul 21, 2026

Last verified

Jul, 2026

Keywords

  • PDGF
  • aging skin
  • post-laser treatment
  • ariessence

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Lynch Regenerative Medicine on 2026-07-21.